Two recombinant human interferon-beta 1a pharmaceutical preparations produce a similar transcriptional response determined using whole genome microarray analysis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 2, 2008, Pages 64-71

  Sterin Prync, A E ^a   Yankilevich, P ^a   Barrero, P R ^b   Bello, R ^a   Marangunich, L ^a   Vidal, A ^a   Criscuolo, M ^a   Benasayag, L ^c   Famulari, A L ^d   Dominguez R O ^d   Kauffman, M A ^a   Diez, R A ^a  

^a Bio Sidus   (Argentina)

^b HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^c Centro Neurologico   (Argentina)

^d Hospital Sirio Libanés   (Argentina)

Author keywords

Biosimilars; Interferon beta; Lymphocytes; Microarrays; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; BLASTOFERON; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; MYXOVIRUS RESISTANCE PROTEIN A; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; EX VIVO STUDY; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME ANALYSIS; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHARMACOGENOMICS; RELAPSE; REMISSION; RNA HYBRIDIZATION; TRANSCRIPTION REGULATION;

EID: 39049092594     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp46064     Document Type: Article

References (26)

1. Baranzini SE, Mousavi P, Rio J et al. Transcription-based prediction of response to IFN-β using supervised computational methods. PLoS Biol. 2005; 3: e2.
2. Buttmann M, Berberich-Siebelt F, Serfling E et al. Interferon-beta is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/ CXCL10 expression in primary human endothelial cells. J Vasc Res. 2006; 44: 51-60.
3. Comabella M, Martin R. Genomics in multiple sclerosis -current state and future directions. J Neuroimmunol. 2007; 187: 1-8.
4. Dennis G Jr, Sherman BT, Hosack DA et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003; 4: P3.
5. Dudoit S, Gentleman RC, Quackenbush J. Open source software for the analysis of microarray data. Biotechniques. 2003; Suppl: 45-51.
6. Efron B, Tibshirani R. Empirical Bayes methods and false discovery rates for microarrays. Genet Epidemiol. 2002; 23: 70-86.
7. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006; 52: 61-76.
8. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med. 1990; 9: 811-818.
9. Ji H, Davis RW. Data quality in genomics and microarrays. Nat Biotechnol. 2006; 24: 1112-1113.
10. Knight E Jr, Fahey D. Human interferon-beta: effects of deglycosylation. J Interferon Res. 1982; 2: 421-429.
11. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50: 121-127.
12. Munafo A, Trinchard-Lugan II, Nguyen TX et al. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol. 1998; 5: 187-193.
13. Panitch H, Goodin DS, Francis G et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002; 59: 1496-1506.
14. Patterson TA, Lobenhofer EK, Fulmer-Smentek SB et al. Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) Project. Nat Biotechnol. 2006; 24: 1140-1150.
15. Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology (Carlton). 2006; 11: 341-346.
16. Rogge MC, Simonian NA, Jones WE. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol. 1999; 6: 375-377.
17. Satoh J, Nakanishi M, Koike F et al. T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients. J Neuroimmunol. 2006a; 174: 108-118.
18. Satoh J, Nanri Y, Tabunoki H et al. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis. BMC Neurol. 2006b; 6: 18.
19. Shi L, Reid LH, Jones WD et al. The MicroArray Quality Control (MAQC) Project shows inter- and intra-platform reproducibility of gene expression measurements. Nat Biotechnol. 2006; 24: 1151-1161.
20. Sibley W, Group IMSS. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993; 43: 655-661.
21. Smyth G. Limma: linear models for microarray data. In: Gentleman RC, Dudoit S, Irizarry R, Huber W (eds). Bioinformatics and computational biology solutions using R and bioconductor. NewYork: Springer; 2005.
22. Stoughton RB, Friend SH. How molecular profiling could revolutionize drug discovery. Nat Rev Drug Discov. 2005; 4: 345-350.
23. Sturzebecher S, Randinger KP, Rosenwald A et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain. 2003; 126: 1419-1429.
24. Utsumi J, Mizuno Y Hosoi K et al. Characterization of four different mammalian-cell-derived recombinant human interferon-beta 1a. Identical polypeptides and non-identical carbohydrate moieties compared to natural ones. Eur J Biochem. 1989; 181: 545-553.
25. Weinstock-Guttman B, Badgett D, Patrick K et al. Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol. 2003; 171: 2694-2702.
26. Yauk CL, Berndt ML, Williams A et al. Comprehensive comparison of six microarray technologies. Nucleic Acids Res. 2004; 32: e124.